Market Cap | 147.11M | P/E | - | EPS this Y | 26.30% | Ern Qtrly Grth | - |
Income | -75.52M | Forward P/E | -1.98 | EPS next Y | - | 50D Avg Chg | 6.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | 1.71 | EPS next 5Y | - | 52W High Chg | -81.00% |
Recommedations | 2.00 | Quick Ratio | 4.80 | Shares Outstanding | 256.50M | 52W Low Chg | 30.00% |
Insider Own | 1.45% | ROA | -53.07% | Shares Float | 252.38M | Beta | 3.68 |
Inst Own | 10.34% | ROE | -98.28% | Shares Shorted/Prior | 36.65M/23.71M | Price | 0.57 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 7,785,711 | Target Price | 6.33 |
Oper. Margin | - | Earnings Date | Mar 27 | Volume | 3,810,886 | Change | -5.14% |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
HC Wainwright & Co. | Buy | Feb 22, 24 |
HC Wainwright & Co. | Buy | Jan 24, 24 |
Cantor Fitzgerald | Overweight | Aug 31, 23 |
HC Wainwright & Co. | Buy | Aug 23, 23 |
Chardan Capital | Buy | May 8, 23 |
HC Wainwright & Co. | Buy | Apr 17, 23 |
Chardan Capital | Buy | Apr 14, 23 |
Chardan Capital | Buy | Mar 1, 23 |
Mizuho | Buy | Mar 1, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Sell | 1.28 | 100,000 | 128,000 | 2,227,950 | 01/19/23 |
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Option | 0.51 | 100,000 | 51,000 | 2,327,950 | 01/19/23 |
Kumar Ramesh | Director Director | Apr 18 | Option | 0.51 | 7,500 | 3,825 | 7,500 | 04/20/22 |
Kumar Ramesh | Director Director | Apr 18 | Sell | 2.83 | 7,500 | 21,225 | 04/20/22 | |
Zhang Junge | Director Director | Mar 03 | Option | 1.17 | 88,000 | 102,960 | 88,000 | 03/04/22 |
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Feb 14 | Option | 0.33 | 90,000 | 29,700 | 842,540 | 02/16/22 |
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Feb 14 | Sell | 3.74 | 90,000 | 336,600 | 752,540 | 02/16/22 |
Potti Manish | Director Director | Dec 16 | Option | 1.17 | 45,000 | 52,650 | 45,000 | 12/17/21 |
Kompella Uday | Director Director | Nov 01 | Sell | 15.03 | 50,000 | 751,500 | 154,416 | 11/03/21 |
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Option | 0.51 | 115,367 | 58,837 | 521,367 | 11/03/21 |
Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Sell | 14.15 | 115,367 | 1,632,443 | 406,000 | 11/03/21 |
Kompella Uday | Director Director | Oct 18 | Sell | 8.72 | 201,731 | 1,759,094 | 277,685 | 10/20/21 |
Kumar Ramesh | Director Director | Oct 18 | Option | 0.51 | 7,500 | 3,825 | 7,500 | 10/20/21 |
Kumar Ramesh | Director Director | Oct 18 | Sell | 8.13 | 7,500 | 60,975 | 10/20/21 | |
Kompella Uday | Director Director | Jul 30 | Option | 1.83 | 10,000 | 18,300 | 560,674 | 07/30/21 |